ManzanoGSRiceDRKlawiterEC, et al. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study. Mult Scler2022; 28(7): 1146–1150.
2.
TakashitaEKinoshitaNYamayoshiS, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med2022; 386(10): 995–998.
3.
ShiehzadeganSAlaghemandNFoxM, et al. Analysis of the delta variant B.1.617.2 COVID-19. Clin Pract2021; 11(4): 778–784.
4.
SormaniMPIngleseMSchiavettiI, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. Ebiomedicine2021; 72: 103581.
5.
SormaniMPSchiavettiICarmiscianoL, et al. COVID-19 severity in multiple sclerosis: Putting data into context. Neurol Neuroimmunol Neuroinflamm2021; 9(1): e1105.
